Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Phase 3 Withdrawn Fundacion Clinic per a la Recerca Biomédica

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.

Timeline

Start: 2016-08-03
Primary completion: 2017-06-01
Completion: 2017-06-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Elbasvir	Small molecule	50 mg	—
Subject	GRAZOPREVIR ANHYDROUS	Small molecule	100 mg	—
Background	Ribavirin	Small molecule	1200 mg	—

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

Summary

Timeline

Drugs

Indications